Attorney General Dan Rayfield has announced a new settlement in Oregon’s ongoing fight against generic drug price fixing. On February 2, 2026, the Oregon Department of Justice confirmed that the state, along with 48 others, reached agreement with pharmaceutical companies Lannett Company, Inc. and Bausch Health US, LLC (including Bausch Health Americas, Inc.), resolving long-standing allegations of price-fixing involving generic medications. The total settlement amounts to $17.85 million. All participating states will share in the recovery. The terms include commitments from both companies to cooperate in ongoing litigation and to implement internal reforms designed to ensure fair competition and compliance with antitrust laws.

“In pursuing accountability and putting people over profits, this settlement holds companies responsible for systems that elevated drug prices and harmed families across the state,” Rayfield’s office declared. The original allegations cover conduct between May 2009 and December 2019 involving conspiracies to inflate prices, reduce competition, and unreasonably restrain trade in the generic drug market. Those who purchased affected Lannett or Bausch products during that period may be eligible for compensation. Information about eligibility and claims is available online through the multi-state settlement portal or by calling the designated toll-free number.